Search results for "LIPIDS"

showing 10 items of 2228 documents

Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus.

2010

Background To examine the association of biochemical markers of risk (plasma Hcy, microalbuminuria, lipoprotein (a)(Lp(a)) and diabetic dyslipidaemia) with the prevalence of diabetic foot ulceration in type 2 diabetic patients. Methods Case/control study conducted in 198 type 2 diabetic patients. 89 patients have foot ulcers and 109 have no foot ulcers (control group), in order to establish ORs for diabetic foot ulceration. In all subjects plasma Hcy, Lp(a), total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, HbA1c and microalbuminuria were measured using standard procedures. Results Plasma Hcy, microalbuminuria, HbA…

AdultMaleRiskmedicine.medical_specialtyHomocysteineEndocrinology Diabetes and MetabolismBlood lipidsType 2 diabetesGastroenterologychemistry.chemical_compoundEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansHomocysteineAgedApolipoproteins BGlycated HemoglobinPeripheral Vascular Diseasesbusiness.industryType 2 Diabetes MellitusMiddle Agedmedicine.diseaseDiabetic footDiabetic FootEndocrinologychemistryDiabetes Mellitus Type 2Case-Control StudiesMicroalbuminuriaFemalebusinessLipoproteinDiabetes/metabolism research and reviews
researchProduct

Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with fam…

2009

Eur J Clin Invest 2010; 40 (2): 89–94 Abstract Background  Few data are available on circulating mononuclear cells nuclear factor-kappa B (NF-kB) activity and plasma xanthine oxidase (XO) activity in heterozygous familial hypercholesterolaemia (FH). The goal of the study was to analyse circulating mononuclear cells NF-kB and plasma XO activities in FH patients. Materials and methods  Thirty FH index patients and 30 normoglycaemic normocholesterolaemic controls matched by age, gender, body mass index, abdominal circumference and homeostasis model assessment index were studied. Plasma XO and inflammatory markers were measured by standard methods. NF-kB was assayed in circulating mononuclear c…

AdultMaleRiskmedicine.medical_specialtyXanthine OxidaseApolipoprotein BLipoproteinsClinical BiochemistryBlood lipidsBiochemistryPeripheral blood mononuclear cellMonocytesHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicineBlood plasmamedicineHumansXanthine oxidaseInflammationbiologyCholesterolInterleukin-6C-reactive proteinNF-kappa BGeneral MedicineMiddle AgedEndocrinologychemistryCardiovascular Diseasesbiology.proteinRegression Analysislipids (amino acids peptides and proteins)FemaleBiomarkersLipoproteinInterleukin-1European journal of clinical investigation
researchProduct

Recovery of hormonal, blood lipid, and hematological profiles from a North Pole expedition.

2011

INTRODUCTION This study examined the recovery patterns of hormonal, blood lipid, and hematological profiles following strenuous physical loading, continuous extreme cold exposure and energy deficit induced by a North Pole expedition. METHODS Seven men completed an 850-km North Pole expedition in temperatures varying from -3 degrees C to -47 degrees C. Daily energy intake was approximately 23 MJ x d(-1) and was composed of approximately 60% fat. Blood samples were collected 2 wk before (Pre) the expedition and after 2 wk (Post 1), and 2 mo (Post 2). Additional samples were collected on the first (R1), third (R3), and fifth (R5) return days. RESULTS Mean weight loss upon return was 10 kg. Ene…

AdultMaleSerummedicine.medical_specialtyGlobulinBlood lipidsHematocritWeight lossStress PhysiologicalInternal medicinemedicineHumansExerciseTestosteroneHematologic Testsmedicine.diagnostic_testbiologyArctic RegionsPublic Health Environmental and Occupational HealthCold ClimateLipidsCold TemperatureEndocrinologybiology.proteinHemoglobinmedicine.symptomEnergy MetabolismHormoneLipoproteinAviation, space, and environmental medicine
researchProduct

Obesity, hypertension and atherosclerosis

1993

Hypertension and obesity are associated with an increased risk of clinical cardiovascular complications due to atherosclerosis. Moreover has been reported that hypertension may predispose to atheroma development. In the present review some common aspects to hypertension and atherosclerosis including smooth muscle cell proliferation, endothelial damage and intervention of growth factors have been analyzed. Additional data have to be provided to explain if the connections between hypertension and atherosclerosis could be considered two effects with one unknown cause. In addition some aspects related to obesity and atherosclerosis have been dissected. In particular we have reported our results…

AdultMaleSettore MED/09 - Medicina InternaArteriosclerosisMyocardial InfarctionLipidsSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareBlood Coagulation FactorsObesity hypertension atherosclerosisRisk FactorsHypertensionPrevalenceHumansFemaleObesity
researchProduct

HDL subfractions distribution in renal transplant recipients: Lack of evidence of a reduction of HDL2 particles

1996

Since the high rate of cardiovascular disease in renal transplant recipients, alterations of lipoprotein profile in such patients were extensively evaluated, but the HDL subclass profile was not completely clarified. Renal transplant recipients usually show normal to high plasma levels of HDL cholesterol, even if some investigations suggested a persistence of low HDL2 levels: this was not useful in terms of cardiovascular protection. We designed this study in order to evaluate HDL subfractions distribution in renal transplant recipients. We studied 55 renal transplant recipients, treated with prednisone, azathioprine and/or cyclosporine, and 34 healthy normolipidemics as controls. In all su…

AdultMaleSettore MED/09 - Medicina InternaHDLCholesterol HDLMiddle AgedKidney TransplantationLipidsApolipoproteinsCardiovascular DiseasesRisk FactorsNephrologyMultivariate AnalysisRenal transplant recipientHumansFemaleKidney DiseasesLipoproteinAged
researchProduct

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

2010

Abstract Objective This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity …

AdultMaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinRandomizationAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical BiochemistryUrologyPharmacologyYoung AdultEndocrinologyEzetimibemedicineHumansPotencyRosuvastatinRosuvastatin Calciumlcsh:RC620-627AgedBiochemistry medicalAged 80 and overSulfonamidesSimvastatin; Ezetimibe;hypercholesterolemic;ChemistryhypercholesterolemicResearchAnticholesteremic AgentsBiochemistry (medical)nutritional and metabolic diseasesMiddle AgedEzetimibeFluorobenzeneslcsh:Nutritional diseases. Deficiency diseasesRosuvastatin CalciumPyrimidinesTreatment OutcomeSimvastatinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugLipids in Health and Disease
researchProduct

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately c…

2009

SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patien…

AdultMaleSimvastatinmedicine.medical_specialtyimvastatinStatinmedicine.drug_classHypercholesterolemiaCoronary Artery DiseaseGastroenterologyhypercholesterolaemicchemistry.chemical_compoundDouble-Blind MethodEzetimibeRisk FactorsInternal medicinemedicineHumansRosuvastatinRosuvastatin CalciumAgedAged 80 and overSulfonamidesbiologybusiness.industryCholesterolCholesterol LDLGeneral MedicineMiddle AgedFluorobenzenesRosuvastatin CalciumPyrimidinesTreatment OutcomeEndocrinologychemistrySimvastatinHMG-CoA reductasebiology.proteinAzetidinesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessezetimibemedicine.drugInternational Journal of Clinical Practice
researchProduct

Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholes…

2001

Abstract Cholesteryl ester transfer protein (CETP) facilitates the exchange of triglycerides (TG) and cholesteryl ester between lipoprotein particles. Subjects with familial hypercholesterolemia (FH) have been reported to have higher CETP activities, which could contribute to the lower high-density lipoprotein-cholesterol (HDL-C) levels and increased cardiovascular risk observed in some of these patients. Several polymorphisms have been reported in the CETP locus; the common TaqlB polymorphism is associated, in normolipidemic subjects, with decreased CETP activity and levels and with increased HDL-C levels. No data is available on the influence of this polymorphism in FH subjects. We have e…

AdultMaleSite-Specific DNA-Methyltransferase (Adenine-Specific)medicine.medical_specialtyGenotypeApolipoprotein BLipoproteinsEndocrinology Diabetes and MetabolismPopulationFamilial hypercholesterolemiaHyperlipoproteinemia Type IIchemistry.chemical_compoundEndocrinologyInternal medicineCholesterylester transfer proteinmedicineHumanseducationNational Cholesterol Education ProgramAllelesGlycoproteinseducation.field_of_studyPolymorphism Geneticbiologymedicine.diagnostic_testmedicine.diseaseCholesterol Ester Transfer ProteinsCholesterolEndocrinologychemistryCardiovascular DiseasesSpainbiology.proteinCholesteryl esterFemalelipids (amino acids peptides and proteins)Carrier ProteinsLipid profileLipoproteinMetabolism
researchProduct

Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients

1997

Little information exists on the concentrations of antidepressants and their metabolites in CSF. We measured plasma and CSF levels of trans-doxepin (trans-DOX) and DOX metabolites in 12 depressed patients treated with DOX (250 mg/day) for 6 days. Spinal taps and blood samples were taken on day 7, 10 h after drug administration. Trans-DOX, cis-desmethyldoxepin (cis-DM-DOX), trans-desmethyldoxepin (trans-DM-DOX) and di-desmethyldoxepin (DDM-DOX) were analyzed in CSF and plasma samples by HPLC with column-switching. Although DOX was given as a mixture of 85% trans-DOX and 15% of the pharmacologically more active cis-DOX, we found similar amounts of cis-DM-DOX and trans-DM-DOX in plasma (59.8 +…

AdultMaleSpinal tapMetabolitemedicine.medical_treatmentmacromolecular substancesPharmacologyHigh-performance liquid chromatographychemistry.chemical_compoundCerebrospinal fluidPharmacokineticspolycyclic compoundsmedicineHumansActive metaboliteCerebrospinal FluidPharmacologyDepressive DisorderChemotherapyorganic chemicalstechnology industry and agricultureMiddle AgedDoxepinfilm.actorcarbohydrates (lipids)chemistryfilmFemaleDoxepinmedicine.drugPsychopharmacology
researchProduct

Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease

1986

The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II-III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg X min for 4 h, with an interval of 2-3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation a…

AdultMaleTime FactorsPlatelet AggregationDiastoleHemodynamicsArterial Occlusive DiseasesPlaceboRandom AllocationDrug DiscoveryHeart ratemedicineHumansPlateletIloprostGenetics (clinical)AgedDose-Response Relationship Drugbusiness.industryHemodynamicsCardiovascular AgentsGeneral MedicineMiddle AgedEpoprostenolBlood pressureAnesthesiaCardiovascular agentDrug EvaluationMolecular MedicineFemalelipids (amino acids peptides and proteins)businesscirculatory and respiratory physiologyIloprostmedicine.drugKlinische Wochenschrift
researchProduct